Comparative Pharmacology
Head-to-head clinical analysis: K LEASE versus KLOR CON M15.
Peer-Reviewed Evidence
Head-to-head clinical analysis: K LEASE versus KLOR CON M15.
K-LEASE vs KLOR-CON M15
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Potassium ion replacement therapy; increases extracellular potassium levels to correct hypokalemia.
Potassium is the major intracellular cation; it is necessary for conduction of nerve impulses, contraction of cardiac, skeletal, and smooth muscle, maintenance of normal renal function, acid-base balance, and carbohydrate metabolism.
1 tablet (25 mEq) orally 2-4 times daily with meals; maximum 100 mEq/day.
Oral: 15 mEq (1 tablet) once daily or as directed; range 15-100 mEq/day divided doses. Maximum 150 mEq/day.
None Documented
None Documented
Not applicable; exogenous potassium is not subject to terminal elimination half-life as it is rapidly redistributed and excreted. Clinical context: the half-life of redistribution is minutes to hours.
Not applicable; potassium is not eliminated by first-order kinetics. Serum potassium decline depends on redistribution and renal function, with a half-life of approximately 1-1.5 hours for acute redistribution but prolonged in renal impairment.
Excreted renally as potassium chloride; elimination is 100% renal. No biliary or fecal excretion.
Renal: >90% as potassium ions; fecal: <5%; biliary: negligible.
Category C
Category C
Potassium Supplement
Potassium Supplement